ClinicalTrials.gg
CompletedNCT07163585Updated Sep 9, 2025

Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy

An interventional study of Brivaracetam and Levetiracetam in Epilepsy, sponsored by RESnTEC, Institute of Research. Completed at 1 site in Pakistan. Open to participants aged 1 Month to 14 Years. Per ClinicalTrials.gov, last updated 2025-09-09.

Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Aug 2024, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
1 Month to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies testing brivaracetam in Epilepsy — 1 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
16th of 34
102 · median 94
Started
2024
with 1 other
No phase
Only one
of the 34
Registered
34th of 34
by date
Lead sponsor
1 of 34
RESnTEC, Institute of Research

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is the only one with no phase, and was the 34th registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

1 of the 34 studies testing brivaracetam in Epilepsy is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 1 Month to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

Despite increasing clinical use of both agents, there is a paucity of head-to-head comparative data on the safety and efficacy of brivaracetam versus levetiracetam as initial monotherapy in children. The present study was therefore designed to compare the safety and efficacy of oral brivaracetam and levetiracetam as monotherapy in children aged one month to 14 years with newly diagnosed epilepsy.

Read the detailed description

Most existing studies have focused on adjunctive use or refractory epilepsy, while evidence in treatment-naïve pediatric populations remains sparse. Addressing this gap is critical, as early and effective seizure control can substantially influence long-term neurodevelopmental outcomes. By evaluating seizure outcomes, tolerability, and adverse effect profiles, this study aims to provide evidence to guide clinicians in selecting the most appropriate first-line anti-seizure medication (ASM) for pediatric patients.

03

Conditions studied

  • Epilepsy

Browse trials for

04

Who can participate

Ages eligible
1 Month to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children of either gender
  • Aged 1 month to 14 years
  • With a clinical diagnosis of newly diagnosed epilepsy

Exclusion criteria

Exclusion Criteria:

  • History of prior use of long-term antiseizure medications
  • Evidence of progressive neurological disease
  • Metabolic abnormalities
  • Structural brain malformations
  • Incompatible with monotherapy
  • Severe systemic comorbidities
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Brivaracetam group

    Patients were given oral brivaracetam in a dose of 1-2 mg/kg/day in two divided doses, titrated to a maximum of 5 mg/kg/day based on clinical response and tolerability.

    Drug: Brivaracetam

  • Experimental
    Levetiracetam group

    Oral levetiracetam was initiated at a dose of 10-20 mg/kg/day in two divided doses, with gradual escalation up to 60 mg/kg/day if needed.

    Drug: Levetiracetam

Interventions

  • Brivaracetam was initiated at a dose of 1-2 mg/kg/day in two divided doses, titrated to a maximum of 5 mg/kg/day based on clinical response and tolerability.

  • Levetiracetam was initiated at a dose of 10-20 mg/kg/day in two divided doses, with gradual escalation up to 60 mg/kg/day if needed.

06

What researchers measure

Primary outcomes

  1. Cessation of seizures

    Cessation of seizures was labeled "yes" when a patient remained seizure free.

    Time frame: Up to 3 months

Secondary outcomes

  1. Adverse events

    Labeled "yes" if any treatment-related adverse events reported.

    Time frame: Up to 3 months

07

Study locations

1 site
  • The Children's Hospital and Institute of Child Health
    Multan, Punjab Province 66000, Pakistan
08

References and documents

Individual participant data

Plan to share: No — Data can be shared on a reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jul 2025, 11 months.

Of 339 non-industry interventional studies with no phase under Epilepsy, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 77. This study's 11 months is below that.

Counting every sponsor, half of 360 studies reached it within 42 months; a quarter within 19 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Sep 9, 2025
StartActual
Aug 1, 2024
Primary completionActual
Jul 31, 2025
CompletionActual
Jul 31, 2025
Last update
Sep 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07163585
Lead sponsor
RESnTEC, Institute of Research
Responsible party
Muhammad Aamir Latif (Research Consultant, RESnTEC, Institute of Research) — Principal investigator
First posted
Sep 9, 2025
Start date
Aug 1, 2024
Primary completion
Jul 31, 2025
Completion
Jul 31, 2025
Last update
Sep 9, 2025

Study contacts

Ikram Rahman
principal investigator · Children's Hospital and institute of Child Health Multan, Pakistan
Nuzhat Rahman, FCPS
study director · Children's Hospital and institute of Child Health Multan, Pakistan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Brivaracetam · Levetiracetam

Start the discussion